

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

<b>Statement of Discontinuation of the study</b>	
<b>Name of Company:</b> GlaxoSmithKline	
<b>Study No:</b> 116775 (EudraCT# 2013-004778-84)	
<b>Product:</b> GSK134612A	
<b>Title :</b> A Phase IIIb, open-label, multi-centric study to evaluate the immunogenicity of one dose of GSK Biologicals' MenACWY-TT conjugate vaccine administered intramuscularly in healthy adolescents aged 10 to 15 years, previously primed with a MenC conjugate vaccine.	
<b>Phase:</b> III	
<b>Study Period:</b> NA	
<b>Centres:</b> NA	
<b>Number of Subjects:</b> 0	
<b>Publications:</b> NA	
<b>Statement on discontinuation of the study:</b> Discontinued by GlaxoSmithKline during preparation of the trial. No patient entered the study, therefore no results / data are available.	